Supplementation of Galatonol 300 mg / Striatin 30 mg in Postpartum Lactating Mothers

The study product is a herbal product containing 300 mg Galatonol bioactive fraction, enriched with 30 mg Striatin bioactive fraction. This lactation supplement has been granted the marketing authorization from Badan Pengawas Obat dan Makanan Republik Indonesia (BPOM RI) as traditional medicine with the indication to enhance breast milk production.

A total of 160 subjects (80 subjects in each group) who have just partus, are planned to participate in this study. Eligible subjects will be allocated in a random and blinded fashion to receive one of the two products (study product or placebo) and to come for follow-up visits at Day 4, 8 and 15 (End of Study).

Inclusion criteria

• Signed informed consent prior to participation in the study.
• Generally healthy women aged >= 18-35 years.
• Having a full-term gestational age (37- 40 weeks, inclusive).
• The infant to breastfed: having normal birth body weight (2500-4000 gr).
• Giving consent and commitment to pursue an exclusive breastfeeding
• Willing to comply with the study protocol.
• Spontaneous delivery.
• Healthy newborn baby

Exclusion criteria

• Difficult breastfeeding due to organic defect;
• Suspected COVID-19 by clinical symptoms.
• LATCH Score < 4;
• Choosing not to breastfeed due to other subjective or objective reasons;
• Having multiple birth;
• Known major medical complications during delivery;
• Known to have breast diseases, such as: mastitis, or malignancies
• Breastfeeding prohibited due to clindamycin injection within the past week.
• History of smoking, alcohol drinking, or any drug abuse
• Known to have any relevant chronic infections or illness and gestational diabetes;
• Known to have disorders of major organs ;
• Taking any medication or supplementation known to have galactagogue properties within the last trimester of pregnancy;
• Taking any non-pharmacological complementary treatment within the last trimester of pregnancy aiming to affect breast milk production.
• Participation in any other interventional clinical studies within 30 days prior to Screening.